Quick Answer
Rallybio Corp reported Stockholders Equity of $57.96 million for the year ending 2025.
- Rallybio Corp showed a decrease of -6.0% in Stockholders Equity from 2024 to 2025.
- This data is from Rallybio Corp's annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$24.06 million | Q2 2020: $153.17 million | Q3 2020: $146.29 million | Q1 2021: $123.25 million | Q2 2021: $112.66 million | Q3 2021: $186.49 million | Q1 2022: $163.04 million | Q2 2022: $147.85 million | Q3 2022: $131.94 million | Q1 2023: $155.20 million | Q2 2023: $139.26 million | Q3 2023: $123.58 million | Q1 2024: $89.16 million | Q2 2024: $80.02 million | Q3 2024: $70.82 million | Q1 2025: $54.07 million | Q2 2025: $45.96 million | Q3 2025: $63.03 million.
- Over the full 7 years of available data (2019 to 2025), Rallybio Corp's Stockholders Equity has grown by 243.7%.
- Historical annual values: Fiscal year 2025: $57.96 million | Fiscal year 2024: $61.65 million | Fiscal year 2023: $106.18 million | Fiscal year 2022: $169.32 million | Fiscal year 2021: $175.60 million | Fiscal year 2020: $136.00 million | Fiscal year 2019: $16.86 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: